Dermatologists have long known that the majority of melanomas arising from the skin are associated with exposure to ultraviolet light, but a presentation at the summer meeting of the American Academy of Dermatology (August 2015, New York) allowed clinicians to deepen their knowledge, and provided a framework on the current understanding of the disease.
Conferences
Top Takeaways from ASCO: Circulating melanoma cells
Circulating melanoma cells at baseline or at the 6-month follow-up point served as an indicator of relapse among patients with stage III melanoma and could serve as a way to detect patients at risk for recurrence.
T-VEC Plus Pembrolizumab Combo Shows Activity in Advanced Melanoma
The combination of the attenuated oncolytic virus talimogene laherparepvec (T-VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma
Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.